Name : Mr. TAPAS BANERJEE (47 /M) Date : 23/03/2024

Address: NEW TOWN-157, AMBEY REGENT, NEAR ECHO PARK, GATE NO-01,

SANTRAGACHI, KOLKATA, KOLKATA, WEST BENGAL, INDIA

Examined by: UHID : AMHL.0002020701

Package: MEDIWHEEL - FULL BODY ANNUAL PLUS WITH TMT MALE HCK AHC No: AMHLAH201265



For corporate health checkup No specific complaints

PRESENT KNOWN ILLNESS

No history of - Hypertension, Thyroid

disorder, Heart disease,

Stroke, Asthma

Diabetes mellitus - type 2; Since - 2 yrs;

Medication - regular

Dyslipidaemia Since - 1 yr; Medication -

regular



NO KNOWN ALLERGY :23/03/2024



Cardiovascular system

- Nil Significant

Respiratory system

- Nil Significant

Gastrointestinal system

- Nil Significant

Genitourinary system

- Nil Significant

Eyes

Vision - normal with glasses

ENT

- Nil Significant

Musculoskeletal system

Spine and joints

- Nil Significant

Skin

- Nil Significant



Present medications

- T Rosuvas 5

T jardiance Met 5/500



Do you have any

allergies?

Do you have any drug

allergies?

Covid 19 - Yes Hospitalization for - No

Covid 19

Jaundice - in childhood



Surgical history - Nil



Marital status - Married

No. of children - 1

Diet - Non Vegetarian

Alcohol - does not consume alcohol

- No

- No

Smoking - No
Chews tobacco - No
Physical activity - Mild

Family history

Father - alive
Mother - alive
Brothers - 1

Diabetes - mother,brother

Hypertension - mother
Coronary artery - none

disease

Cancer - None

Name : Mr. TAPAS BANERJEE (47 /M) UHID : AMHL.0002020701 Date : 23/03/2024

Package: MEDIWHEEL - FULL BODY ANNUAL PLUS WITH TMT MALE HCK

AHC No: AMHLAH201265

PHYSICAL EXAMINATION



General

Build - over weight

 Height
 - 167

 Weight
 - 73

 BMI
 - 26.18

 Pallor
 - No

 Oedema
 - no



Cardiovascular system

Heart rate (Per minute) - 86
Rhythm - Regular

- B.P. Sitting

Systolic(mm of Hg) - 124
Diastolic(mm of Hg) - 88
Heart sounds - S1S2+

Respiratory system

Breath sounds - Normal vesicular breath

sounds



Organomegaly - No Tenderness - No



- No significant finding

Opthalmology consultation

Opthalmology findings - PGVA:RE:6/6 LE:6/6

BCVA:RE:N6 LE:N6

OCULAR MOVEMENT:WNL

ANT.SEG:WNL ADVICE:*To continue present glass Rx *Detail dilated Funduscopy*Review

after 1yr/SOS

Printed By: Benazir Begaum

Package : MEDIWHEEL - FULL BODY ANNUAL PLUS WITH TMT MALE HCK AHC No : AMHLAH201265

| OOMI LETETIALING | GRAM PE | ROFIL | E | | Epithelial Cells | Occasio | ona/hpf | | |
|--|---|--------------------------|-------|-------------------------------|--|---------------|-------------|-------|-----------------|
| Test Name | Result | Unit | Level | Range | Casts: | Not Fou | und | | |
| Hemoglobin | 15.3 | g/dl | | 13.0-17.0 | Crystals: | Not Fou | ınd | | |
| RBC COUNT | 5.82 * | Millio ul | on/ 🛑 | 4.5-5.5 | NOTE : - Urine glucose rechecked and | | | | |
| Hematocrit - Hct: | 46.9 | % | | 41-53 | confirmed by Benedict's test | | s iesi | | |
| MCV | 80.6 * | fl | | 83-101 | URINE SUGAR - POST PRANI | | DIAL | | |
| MCH | 26.3 * | pg | | 27-32 | (QUALITATIVE) Test Name | Result | l lnit | Lovel | Range |
| MCHC | 32.6 | % | | 31.5-34.5 | URINE | +++ | Oilit | Level | Kange |
| RDW | 17.5 * | % | | 11.8-14.0 | GLUCOSE(POST PRANDIAL) | | | | |
| WBC Count | 6700 | /cu n | nm 🗨 | 4000-10000 | | | | | |
| Platelet Count | 1.70 | lacs/ mm | cu • | 1.5-4.0 | URINE SUGAR- FASTING(QUALITATIVE) Test Name Result Unit Level Ran | | Pango | | |
| Neutrophils | 75 | % | | 40-80 | URINE GLUCOSE(FASTING) | +++ | Oilit | Level | ixaliye |
| Lymphocytes | 16 * | % | | 20-40 | | | | | |
| Monocytes | 08 | % | | 2-10 | BLOOD GROUPING | | DINIC (A | NBO A | NU DI |
| Eosinophils | 01 | % | | 01-06 | Test Name | Result | • | | Range |
| Basophils | 00 | % | | 0-0 | ABO Group: | 0 | • | | |
| RBC: | Anisocytosis+, Predominantly Normocytic Normochromic | | | • | Rh (D) Type: | POSITIVE | | | |
| Platelets: | Adequat | Adequate on the smear | | LIVER FUNCTION TEST (PACKAGE) | | | | | |
| | | | | | Test Name | Result | Unit | Level | Range |
| ERYTHROCYTE SEDIMENTATION RATE (ESR) | 2 | mm/ hr | 1st | 0-15 | ALT(SGPT) - SERUM ALBUMIN - SERUM | 22 4.4 | U/L g/dL | • | 0-50 3.5-5.1 |
| URINE ROUTINE AN | ND MICRO | SCOF | Υ | | | | | | |
| Test Name | Result | | | Range | ALKALINE | 96 | U/L | | 43-115 |
| Volume: | 30 | mL | | | PHOSPHATASE - SERUM | | | | |
| Colour: | Pale Str | aw | | | | | | | |
| Appearance | Slightly | Slightly Turbid 1.025 | | | AST (SGOT) - SERUM | 25 | U/L | | 0-50 |
| Specific Gravity | 1.025 | | | | | 0.7 | , ,, | | 0010 |
| pH: | 6.0 | | | | BILIRUBIN TOTAL - SERUM | 0.7 | mg/dL | _ | 0.3-1.2 |
| Albumin: | Not Dete | ected | | | | | | | |
| Glucose | +++ | | | | LIPID PROFILE TEST | • | • | | D |
| Ketone: | Not Dete | ected | | | Test Name CHOLESTEROL - | Result 128 | mg/dL | _ | Range 0-200 |
| Bile Pigments | Not Detected Nil /hpf | | | | SERUM | 120 | mg/uL | _ | 0-200 |
| RBC | | | | | CREATININE - SERLIM | | | | |
| | Occasionalhpf | | | | CREATININE - SERUM Test Name Result Unit Level Range | | | | |

Name : Mr. TAPAS BANERJEE (47 /M) UHID : AMHL.0002020701 **Date** : 23/03/2024 Package: MEDIWHEEL - FULL BODY ANNUAL PLUS WITH TMT MALE HCK AHC No: AMHLAH201265

GLOBULIN: g/dL 3.5 1.8-3.6 mg/dL **CREATININE - SERUM** 0.9 0.9 - 1.3(CALCULATED) -SERUM LIVER FUNCTION TEST (PACKAGE) **Test Name** Result Unit Level Range THYROID PROFILE - I(T3,T4 AND TSH) U/L GGTP: GAMMA 21 0 - 55Level Range **Test Name** Result Unit **GLUTAMYL** ng/ml TOTAL T3: TRI 0.99 0.87-1.78 TRANSPEPTIDASE -**IODOTHYRONINE -SERUM SERUM GLUCOSE - PLASMA (FASTING)** TOTAL T4: 11.36 µg/dL 5.48-14.28 **Test Name** Result Unit Level Range THYROXINE - SERUM GLUCOSE - PLASMA 116 * mg/dL 70-99 (FASTING) LIPID PROFILE TEST (PACKAGE) **Test Name** Result Unit Level Range **GLUCOSE - PLASMA (POST PRANDIAL)** TRIGLYCERIDES -116 mg/dL 0-150 **Test Name** Result Unit Level Range **SERUM** GLUCOSE - PLASMA 215 * mg/dL 70-140 (POST PRANDIAL) THYROID PROFILE - I(T3,T4 AND TSH) **Test Name** Result Unit Level Range **HBA1C (GLYCOSYLATED** TSH: THYROID μIU/mL 2.24 0.38-5.33 HAEMOGLOBIN)-WHOLE BLOOD STIMULATING Result Unit **Test Name** Level Range HORMONE - SERUM 5.7 * % Nondiadetic: 4 HBA1C (GLYCOSYLATED - 5.6 % **URIC ACID - SERUM** HAEMOGLOBIN)-WHO Prediabetics: **Test Name** Result Unit Level Range LE BLOOD 5.7 - 6.4% URIC ACID - SERUM 4.1 mg/dL 2.6-7.2 Diabetes >/= 6.5% LIVER FUNCTION TEST (PACKAGE) ADA Theraputic goal **Test Name** Result Unit Level Range : <7% **BILIRUBIN** 0.2 mg/dL 0.0 - 0.2CONJUGATED LIPID PROFILE TEST (PACKAGE) (DIRECT) - SERUM **Test Name** Result Unit Level Range HDL CHOLESTEROL -39 mg/dL 30-70 PROSTATIC SPECIFIC ANTIGEN (PSA TOTAL) -**SERUM SERUM Test Name** Result Unit Level Range LDL CHOLESTEROL 82 mg/dL Optimal: <100 PROSTATIC SPECIFIC 0.6 ng/mL 0.00 - 6.50-SERUM ANTIGEN (PSA TOTAL) - SERUM VLDL CHOLESTEROL -7 mg/dL 0-35 SERUM (Calculated) **BUN (BLOOD UREA NITROGEN)** LIVER FUNCTION TEST (PACKAGE) **Test Name** Result Unit Level Range **Test Name** Result Unit Level Range BUN (BLOOD UREA 11.9 mg/dL 🔵 7.0-18.0 NITROGEN) PROTEIN TOTAL -7.9 g/dL

Test Name Result Unit Level Range

Borderline High/Low Out of Range Within Normal Range

6.4-8.3

SERUM

Name : Mr. TAPAS BANERJEE (47 /M) UHID : AMHL.0002020701 Date : 23/03/2024

Package: MEDIWHEEL - FULL BODY ANNUAL PLUS WITH TMT MALE HCK

AHC No: AMHLAH201265

A/G - RATIO 1.3 • 1.0-2.0

BUN/CREATININE RATIO

Test Name Result Unit Level Range

BUN/CREATININE 12.7

RATIO

ECG

SINUS RHYTHM WITH SINUS ARRHYTHMIA.

TREADMILL TEST / STRESS TEST

STRESS TEST IS NEGATIVE FOR PROVOCABLE MYOCARDIAL ISCHAEMIA.

ULTRASOUND SCREENING WHOLE ABDOMEN

* Grade I fatty liver.

[NOTE: At times pelvic structures are not well visualized due to inadequate patient preparation / excess bowel gas shadow. However suggested clinical correlation and other investigations if clinically indicated.

X-RAY CHEST PA

* Chest skiagram does not reveal any significant abnormality.

Package: MEDIWHEEL - FULL BODY ANNUAL PLUS WITH TMT MALE HCK

AHC No: AMHLAH201265

Printed By: AHC Physician / Consultant Internal Medicine

Note :- The Health Check-up examinations and routine investigations have certain limitations and may not be able to detect all the diseases. Any new or persisting symptoms should be brought to the attention of the Consulting Physician. Additional tests, consultations and follow up may be required in some cases.

Name : Mr. TAPAS BANERJEE (47 /M) UHID ; AMHL.0002020701 Date ; 23/03/2024

Package: MEDIWHEEL - FULL BODY ANNUAL PLUS WITH TMT MALE HCK

AHC No: AMHLAH201265

AICVD RISK SCORE REPORT

| RISK STATUS | YOUR SCORE | ACCEPTABLE SCORE |
|---------------|------------|------------------|
| Moderate Risk | 6 | 6 |

Your likelihood of developing cardiovascular disease in the next ten years is 1.3 times higher than the people of your age and gender

The AICVD risk score developed by Apollo Hospitals is a novel artificial intelligence-based risk scoring system that predicts your risk of having Coronary Artery Disease (CAD) related events in the next ten years. This scoring system uses Indian data and has been validated by multiple national and international institutions. This risk score is more than 92% accurate and has been compiled based on your physical parameters, heart health attributes, lifestyle and medical history. **Note:** The risk category is determined through the ratio between guest score and acceptable score at multiple decimal points. The outputs are shown in whole numbers.

Based on your AICVD risk score you are advised the following:

- Follow the guidance and education on lifestyle and dietary management provided through the ProHealth program. Maintain a healthy BMI (<25). Avoid tobacco in any form and if you are a smoker, stop smoking.
- Continue with medications for high blood pressure, diabetes, or dyslipidemia, if advised by your physician. Maintain HbA1c <7% (<53mmol/mol), blood pressure <140/90mmHg.
- · Follow your physician's advice regarding follow up tests, consults and annual health assessment
- It is recommended that you visit your physician every 6 months if you have:
 - o Uncontrolled high blood pressure, Diabetes, Dyslipidemia, Coronary heart disease

DISCLAIMER

- 1. This is not a diagnostic tool and it does not guarantee accuracy of the result and cannot be acted upon independently.
- 2. This risk score and clinical algorithm is a general guideline for physicians. Any additional laboratory investigations, diagnostic imaging, treatment or patient education related to lifestyle management is under the physician 's or cardiologist's discretion.
- 3. To ensure the information in the report is up to date, accurate and correct, doctor shall be consulted for interpretation of the report.
- 4. Apollo Hospitals and its staff does not offer any assurance on the information made available or be liable for any loss or damage as the said report is based on the AICVD risk score without any intervention from their side.
- 5. By usage of the AICVD risk score, it is deemed that the beneficiary of this service has agreed to get the same done at his own risk and further agrees with this disclaimer without any limitation or any clauses or sub-clauses.

The Clinical Al Models and APIs used at Apollo Hospitals are certified by ISO 13485 : 2016 vide certificate no. MD 763515